The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

Changes over time for: Section 34

Version Superseded: 06/11/2023

Alternative versions:

Status:

Point in time view as at 25/05/2023. This version of this provision has been superseded.

Status

You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.

Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.

Changes to legislation:

The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, Section 34 is up to date with all changes known to be in force on or before 17 November 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.

Changes to Legislation

Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.

Deferral of consideration of applications for inclusion in a pharmaceutical list on fitness groundsU.K.

This section has no associated Explanatory Memorandum

34.—[F1(A1) In this regulation, “A” means, where an application for inclusion in a pharmaceutical list is made by a person who is—

(a)an individual, the individual making the application;

(b)a partnership, any partner in the partnership making the application; or

(c)a body corporate—

(i)except for the purposes of paragraph (1)(b), (c)(ii), (e), (g), (i) and (k), the body corporate making the application, and

(ii)any director or superintendent of the body corporate making the application.]

(1) An application for inclusion in a pharmaceutical list by a person F2...who is not already included in it may be deferred if the NHSCB is satisfied that—

(a)there are, in respect of A F3...—

(i)criminal proceedings in the United Kingdom, or

(ii)proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,

which, if they result in a conviction, or the equivalent of a conviction, would be likely to lead to [F4the person’s removal from the pharmaceutical list, if the person] were to be included in it;

(b)in respect of a body corporate of which A is, or has in the preceding 6 months been, or was at the time of the originating events, a director or superintendent, there are—

(i)criminal proceedings in the United Kingdom, or

(ii)proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,

which, if they resulted in a conviction, or the equivalent of a conviction, would be likely to lead to [F5the person’s removal from the pharmaceutical list, if the person] were to be included in it;

(c)there is an investigation anywhere in the world—

(i)by A's F6... licensing or regulatory body, or

(ii)relating to A F7... in A's professional capacity (including one by the NHSCB or another primary care organisation),

which, if the outcome were adverse, would be likely to lead to the removal of [F8the person from the pharmaceutical list if the person] were to be included in it;

(d)A F9...is suspended from a relevant list;

(e)a body corporate of which A F10... was, at the time of the originating events, a director or superintendent, is suspended from a relevant list;

(f)the First-tier Tribunal is considering an appeal by A F11... against a decision of the NHSCB or another primary care organisation—

(i)to refuse an application for inclusion in a relevant list, or

(ii)to include A conditionally in, or to remove or contingently remove A from, a relevant list,

and if that appeal were to be unsuccessful, the NHSCB would be likely to remove [F12the person from the pharmaceutical list if the person] were to be included in it;

(g)the First-tier Tribunal is considering an appeal by a body corporate of which A F13... was, at the time of the originating events, or has in the preceding 6 months been, a director or superintendent, against a decision of the NHSCB or another primary care organisation—

(i)to refuse an application by that body corporate for inclusion in its list,

(ii)to include A conditionally in, or to remove or contingently remove A from, a relevant list,

and if that appeal were to be unsuccessful the NHSCB would be likely to remove [F14the person from the pharmaceutical list if the person] were to be included in it;

(h)A F15... is being investigated by the NHS BSA in relation to any fraud, where the result, if adverse, would be likely to lead to the removal of [F16the person from the pharmaceutical list if the person] were to be included in it;

(i)a body corporate, of which A F17...was, at the time of the originating events, a director or superintendent, is being investigated by the NHS BSA in relation to any fraud, where the result if adverse would be likely to lead to the removal of [F18the person from the pharmaceutical list if the person] were to be included in it;

(j)the First-tier Tribunal is considering an application from the NHSCB or a Local Health Board for a national disqualification of A F19...;

(k)the First-tier Tribunal is considering an application from the NHSCB or a Local Health Board for a national disqualification of a body corporate of which A F20... was, at the time of the originating events, a director or superintendent; or

(l)the NHSCB or another primary care organisation, for a reason relating to unsuitability, fraud or efficiency of service provision—

(i)is considering removal (other than voluntary removal) or contingent removal of the applicant from a relevant list, or

(ii)has taken a decision to remove (other than voluntary removal) or contingently remove [F21the applicant] from a relevant list but that decision has yet to take effect.

(2) The NHSCB may only defer a decision under paragraph (1) until—

(a)the outcome of the cause for the deferral is known; or

(b)the reason for the deferral no longer exists.

Textual Amendments

F1Reg. 34(A1) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(a)

F2Word in reg. 34(1) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(i)

F3Words in reg. 34(1)(a) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(aa)

F4Words in reg. 34(1)(a) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(bb)

F5Words in reg. 34(1)(b) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iii)

F6Words in reg. 34(1)(c)(i) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(aa)

F7Words in reg. 34(1)(c)(ii) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(bb)

F8Words in reg. 34(1)(c) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(cc)